An international study led by Mayo Clinic researchers has identified interleukin-6 (IL-6) receptor blockers as a promising option for preventing relapses in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is a rare autoimmune neurological disorder that can cause vision loss, paralysis and other serious neurological complications. In some patients, the disease causes repeated inflammatory attacks, or relapses, that can lead to accumulating neurological disability. The study focused on two medications, tocilizumab and satralizumab, that belong to a class of drugs known as IL-6 receptor blockers. This multinational collaboration allowed researchers to evaluate outcomes across various patient populations while expanding the evidence for IL-6 receptor blockade in MOGAD.